| Literature DB >> 27914475 |
Joshua R Francis1,2,3, Peter Richmond4,5,6, Christine Robins6, Katie Lindsay7, Avram Levy8,9, Paul V Effler10, Meredith Borland5,11,12, Christopher C Blyth5,6,7,13.
Abstract
BACKGROUND: Febrile seizures are common in young children. Annual peaks in incidence mirror increased respiratory virus activity during winter. Limited virological data are available using modern diagnostic techniques for children with febrile seizures. We aimed to determine the frequency of detection of specific viral pathogens in children with febrile seizures, to describe risk factors including recent vaccination and clinical features associated with specific etiologies.Entities:
Keywords: Adenovirus; Enterovirus; Febrile seizures; Immunization; Influenza
Mesh:
Year: 2016 PMID: 27914475 PMCID: PMC5135752 DOI: 10.1186/s12887-016-0740-5
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Fig. 1Enrolment flow chart
Viral pathogens identified in isolation and in co-infection
| Virus identified | Single infection | Viral co-infection | Total cases ( |
|---|---|---|---|
| Rhinovirus | 6/31 (19%) | 25/31 (81%) | 31 (22%) |
| - RV-A | 18 | ||
| - RV-C | 13 | ||
| Adenovirus | 6/30 (20%) | 24/30 (80%) | 30 (21%) |
| Enterovirus | 12/29 (41%) | 16/28 (57%) | 28 (20%) |
| - Coxsackie A2 | 2 | ||
| - Coxsackie A4 | 5 | ||
| - Coxsackie A5 | 2 | ||
| - Coxsackie A6 | 5 | ||
| - Coxsackie A9 | 1 | ||
| - Coxsackie A14 | 1 | ||
| - Coxsackie B1 | 2 | ||
| - Coxsackie B2 | 2 | ||
| - Cosxackie B4 | 1 | ||
| - Echo6 | 2 | ||
| - Echo9 | 1 | ||
| - Echo14 | 1 | ||
| - Echo19 | 1 | ||
| - Echo30 | 1 | ||
| Influenza | 11/19 (58%) | 8/19 (42%) | 19 (13%) |
| - A/H3N2 | 13 | ||
| - A/H1N1 | 0 | ||
| - B | 6 | ||
| Human Herpesvirus 6 | 3/17 (18%) | 14/17 (82%) | 17 (12%) |
| Coronavirus | 2/13 (15%) | 11/13 (85%) | 13 (9%) |
| - HCOV-OC43 | 8 | ||
| - HCOV-NL63 | 2 | ||
| - HCOV-HKU1 | 2 | ||
| - HCOV0HL63 | 1 | ||
| Respiratory Syncytial Virus | 6/13 (46%) | 7/13 (54%) | 13 (9%) |
| - RSVA | 8 | ||
| - RSVB | 3 | ||
| Human Bocavirus | 2/13 (15%) | 11/13 (85%) | 13 (9%) |
| Parainfluenza III | 4/7 (57%) | 3/7 (43%) | 7 (5%) |
| Human metapneumovirus | 2/5 (40%) | 3/5 (60%) | 5 (3%) |
Impact of viral pathogens on clinical presentation and management
| Simple FS | Complex FS | Anticonvulsant given | Admission | |
|---|---|---|---|---|
| No virus ( | 28 (68%) | 13 (32%) | 6 (15%) | 19 (46%) |
| One virus ( | 36 (67%) | 17 (31%) | 5 (9%) | 21 (39%) |
| Two or more viruses ( | 30 (63%) | 16 (33%) | 7 (15%) | 27 (56%) |
| Rhinovirus ( | 19 (61%) | 11 (35%) | 5 (16%) | 14 (45%) |
| Adenovirus ( | 21 (70%) | 7 (23%) | 3 (10%) | 16 (53%) |
| Enterovirus ( | 19 (68%) | 9 (32%) | 1 (4%) | 14 (50%) |
| Influenza ( | 9 (47%) | 8 (42%) | 1 (5%) | 8 (42%) |
| HHV6 ( | 10 (59%) | 7 (41%) | 2 (12%) | 10 (59%) |
Impact of recent immunization on clinical presentation and management
| Simple FS | Complex FS | Anticonvulsant given | Admission | |
|---|---|---|---|---|
| Any vaccine ( | 13 (81%) | 3 (19%) | 1 (6%) | 8 (50%) |
| MMR ( | 11 (79%) | 3 (21%) | 1 (7%) | 7 (50%) |
| Vaccine plus virus detected ( | 8 (89%) | 1 (11%) | 0 | 3 (33%) |
| No vaccine ( | 85 (63%) | 47 (35%) | 18 (13%) | 64 (47%) |